Mattsson C, Nilsson S, Häggroth L
Thromb Res. 1983 Apr 1;30(1):91-100. doi: 10.1016/0049-3848(83)90400-0.
The thrombolytic activity and elimination rate in vivo of a plasminogen activator purified from a melanoma cell line was examined in a rabbit thrombus model. Following an intravenous injection of 125I labelled plasminogen activator, its biological activity disappeared very rapidly from the plasma (t1/2 = 1.5 min) and radioactivity immediately accumulated in the liver. After a two-hour infusion with a total amount of 0.5 mg plasminogen activator a 60 per cent reduction in the weight of partially occluding thrombi was noted. No significant thrombolysis was seen in totally occluded vessels. Treatment with 0.5 mg plasminogen activator caused no depletion of fibrinogen or alpha 2-antiplasmin. No significant thrombolysis occurred after infusion of 0.5 mg streptokinase, but total lysis of occluding and non-occluding thrombi was obtained after a two-hour infusion of 1 mg streptokinase, without any reduction of fibrinogen. A marked reduction of alpha 2-antiplasmin was seen after both 0.5 and 1 mg of streptokinase treatment but were not seen in rabbits infused with plasminogen activator.
在兔血栓模型中检测了从黑色素瘤细胞系纯化的纤溶酶原激活剂的溶栓活性和体内消除率。静脉注射125I标记的纤溶酶原激活剂后，其生物活性在血浆中迅速消失（半衰期=1.5分钟），放射性立即在肝脏中蓄积。在以总量0.5毫克纤溶酶原激活剂进行两小时输注后，观察到部分阻塞性血栓的重量减少了60%。在完全阻塞的血管中未见明显溶栓现象。用0.5毫克纤溶酶原激活剂治疗未导致纤维蛋白原或α2抗纤溶酶的消耗。输注0.5毫克链激酶后未发生明显溶栓，但在输注1毫克链激酶两小时后，阻塞性和非阻塞性血栓均完全溶解，且纤维蛋白原未减少。在0.5毫克和1毫克链激酶治疗后均可见α2抗纤溶酶明显降低，但在输注纤溶酶原激活剂的兔中未见此现象。
